Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 5/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168090 | 0.88 | KDM4E (0.44) | HCRTR1HCRTR2MEN1KMT2AALOX15 | |
| SCHEMBL15846857 | 0.80 | MAPK1 (0.51) | HCRTR1HCRTR2CNR2CNR1KMT2A | |
| SCHEMBL168763 | 0.80 | HCRTR1 (0.46) | HCRTR1HCRTR2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL166166 | 0.80 | HCRTR1 (0.58) | HCRTR1HCRTR2CNR1MEN1KMT2A | |
| SCHEMBL5058405 | 0.74 | SMN1; SMN2 (0.55) | HCRTR1HCRTR2KMT2ASMN1; SMN2MAPK1 | |
| Hydrochloric Acid SCHEMBL5054616 | 0.73 | SMN1; SMN2 (0.54) | HCRTR1HCRTR2KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL28397734 | 0.73 | HCRTR1 (0.59) | HCRTR1HCRTR2CNR2CNR1MEN1 | |
| SCHEMBL5216465 | 0.72 | HCRTR1 (0.60) | HCRTR1HCRTR2CNR1SMN1; SMN2MAPK1 | |
| SCHEMBL1421327 | 0.72 | SMN1; SMN2 (0.55) | HCRTR1HCRTR2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2781032 | 0.72 | SMN1; SMN2 (0.55) | HCRTR1HCRTR2MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365551-B2 | 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2016-06-14 | — | — | US | disclosed |
| EP-2611772-B1 | 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| EP-2611772-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028629-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | LRRK2, PARK7, BRSK2 | HCRTR1 4213/4885HCRTR2 3121/4885CNR2 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.